Detection of human papillomavirus type 16 by goldnanoparticle immunoagglutination

Abstract

Cervical cancer is the second leading cause of cancer deaths in women worldwide. More than 470,000 cases are diagnosed each year. Development of cervical cancer is associated with persistent of high-risk HPV infection especially type 16 and 18. Now, methods for screening cervical cancer can be divided into detection of cerical cell dysplasia and detection of HPV DNA. Several attempts in developing a new diagnostic method have been made. To accomplish this objective, the optical detection assay of HPV type 16 antigens using goldnanoparticle based on immunoagglutination was developed. The assay used AuNPs conjugated with either HPV-16L1 or HPV-16E6 polyclonal antibodies for detecting HPV-16 L1 or E6 proteins directly from clinical specimens and the result was visibly detected by an agglutinate of the reaction. In this study, a total of 40 samples obtained from patients with normal-pathology, LSIL, HSIL and CaCx, were detected of HPV-16 by the newly assay and type-specific PCR. The result showed that 25 samples were detected with HPV-16 by type-specific PCR. All 25 HPV-16 samples were positive for HPV16L1 60% (15/25) and HPV16E6 36% (9/25). Therefore, the sensitivity of the assay was 60% (15/25) for HPV-16L1 detection and 36%(9/25) for HPV-16E6 detection which is sensitive less than detection by type specific PCR. However, in high grade CIN3 and CaCx samples sensitivity of the assay for detection HPV-16E6 was reached to 69.23% (9/13). These results indicated that the immunogoldagglutination assay for detect HPV16E6 might be an appropriate for screening cervical pre cancerous and cancerous patients.